vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and Silvercrest Asset Management Group Inc. (SAMG). Click either name above to swap in a different company.
Silvercrest Asset Management Group Inc. is the larger business by last-quarter revenue ($32.0M vs $16.1M, roughly 2.0× Journey Medical Corp). Silvercrest Asset Management Group Inc. runs the higher net margin — -0.4% vs -7.8%, a 7.4% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -0.0%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs 2.7%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
DERM vs SAMG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $32.0M |
| Net Profit | $-1.2M | $-120.0K |
| Gross Margin | — | — |
| Operating Margin | -2.8% | -2.8% |
| Net Margin | -7.8% | -0.4% |
| Revenue YoY | 27.3% | -0.0% |
| Net Profit YoY | -182.0% | -107.4% |
| EPS (diluted) | $-0.04 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $32.0M | ||
| Q3 25 | $17.0M | $31.3M | ||
| Q2 25 | $15.0M | $30.7M | ||
| Q1 25 | $13.1M | $31.4M | ||
| Q4 24 | $12.6M | $32.0M | ||
| Q3 24 | $14.6M | $30.4M | ||
| Q2 24 | $14.9M | $31.0M | ||
| Q1 24 | $13.0M | $30.3M |
| Q4 25 | $-1.2M | $-120.0K | ||
| Q3 25 | $-2.3M | $618.0K | ||
| Q2 25 | $-3.8M | $1.9M | ||
| Q1 25 | $-4.1M | $2.5M | ||
| Q4 24 | $1.5M | $1.6M | ||
| Q3 24 | $-2.4M | $2.3M | ||
| Q2 24 | $-3.4M | $2.7M | ||
| Q1 24 | $-10.4M | $3.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
| Q4 25 | -2.8% | -2.8% | ||
| Q3 25 | -9.0% | 4.3% | ||
| Q2 25 | -19.2% | 13.2% | ||
| Q1 25 | -25.3% | 15.4% | ||
| Q4 24 | 17.7% | 6.1% | ||
| Q3 24 | -19.8% | 14.6% | ||
| Q2 24 | -19.7% | 17.1% | ||
| Q1 24 | -77.4% | 19.5% |
| Q4 25 | -7.8% | -0.4% | ||
| Q3 25 | -13.6% | 2.0% | ||
| Q2 25 | -25.3% | 6.3% | ||
| Q1 25 | -31.0% | 7.9% | ||
| Q4 24 | 12.1% | 5.1% | ||
| Q3 24 | -16.3% | 7.4% | ||
| Q2 24 | -22.6% | 8.6% | ||
| Q1 24 | -80.1% | 9.9% |
| Q4 25 | $-0.04 | $0.02 | ||
| Q3 25 | $-0.09 | $0.07 | ||
| Q2 25 | $-0.16 | $0.21 | ||
| Q1 25 | $-0.18 | $0.26 | ||
| Q4 24 | $0.10 | $0.16 | ||
| Q3 24 | $-0.12 | $0.24 | ||
| Q2 24 | $-0.17 | $0.28 | ||
| Q1 24 | $-0.53 | $0.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $44.1M |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $50.3M |
| Total Assets | $94.6M | $166.6M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $44.1M | ||
| Q3 25 | $24.9M | $36.1M | ||
| Q2 25 | $20.3M | $30.0M | ||
| Q1 25 | $21.1M | $36.3M | ||
| Q4 24 | $20.3M | $68.6M | ||
| Q3 24 | $22.5M | $58.1M | ||
| Q2 24 | $23.9M | $49.9M | ||
| Q1 24 | $24.1M | $39.7M |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $50.3M | ||
| Q3 25 | $25.9M | $58.9M | ||
| Q2 25 | $19.2M | $64.6M | ||
| Q1 25 | $21.5M | $80.0M | ||
| Q4 24 | $20.1M | $80.7M | ||
| Q3 24 | $10.9M | $84.6M | ||
| Q2 24 | $11.3M | $85.3M | ||
| Q1 24 | $13.0M | $83.9M |
| Q4 25 | $94.6M | $166.6M | ||
| Q3 25 | $85.2M | $157.6M | ||
| Q2 25 | $81.2M | $152.7M | ||
| Q1 25 | $85.0M | $159.9M | ||
| Q4 24 | $80.2M | $194.4M | ||
| Q3 24 | $64.0M | $184.2M | ||
| Q2 24 | $65.2M | $177.6M | ||
| Q1 24 | $66.6M | $170.2M |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $18.6M |
| Free Cash FlowOCF − Capex | — | $15.0M |
| FCF MarginFCF / Revenue | — | 46.9% |
| Capex IntensityCapex / Revenue | — | 11.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $17.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $18.6M | ||
| Q3 25 | $-2.4M | $14.6M | ||
| Q2 25 | $-942.0K | $13.8M | ||
| Q1 25 | $-2.8M | $-24.7M | ||
| Q4 24 | $2.2M | $21.6M | ||
| Q3 24 | $-1.2M | $13.3M | ||
| Q2 24 | $-5.2M | $16.0M | ||
| Q1 24 | $-5.0M | $-24.1M |
| Q4 25 | — | $15.0M | ||
| Q3 25 | — | $13.8M | ||
| Q2 25 | — | $13.4M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $19.9M | ||
| Q3 24 | — | $12.9M | ||
| Q2 24 | — | $15.6M | ||
| Q1 24 | — | $-24.7M |
| Q4 25 | — | 46.9% | ||
| Q3 25 | — | 44.1% | ||
| Q2 25 | — | 43.6% | ||
| Q1 25 | — | -80.0% | ||
| Q4 24 | — | 62.2% | ||
| Q3 24 | — | 42.4% | ||
| Q2 24 | — | 50.4% | ||
| Q1 24 | — | -81.6% |
| Q4 25 | — | 11.4% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 5.3% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 2.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 23.62× | ||
| Q2 25 | — | 7.22× | ||
| Q1 25 | — | -10.01× | ||
| Q4 24 | 1.46× | 13.34× | ||
| Q3 24 | — | 5.90× | ||
| Q2 24 | — | 6.00× | ||
| Q1 24 | — | -8.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
SAMG
| Investment Advisory Management And Administrative Service | $30.7M | 96% |
| Tax And Family Office Services | $1.2M | 4% |
